Member login | Not a member? Sign up
Proximagen is researching and developing treatments for neurodegenerative diseases. It is working on four main groups of compounds. PRX1 is for Parkinson's disease, PRX2 is for the treatment of dyskinesia or involuntary movements, PRX4 is for neuroprotection of human nerve cells and PRX5 is designed to reduce cognitive decline.
Keep up to date with articles published at AIMMicro.com. Subscribe to AIM Micro RSS Feeds